Kanyos Bio

Kanyos Bio, founded in 2015 and headquartered in Massachusetts, USA, is a biotechnology company. The company is committed to providing more effective treatments for autoimmune diseases and is developing immunotherapies for Type 1 diabetes and celiac disease. Kanyos Bio's proprietary immune tolerance platform utilizes proteins or antigens, aiming to deliver precise, targeted disease treatment without the side effects associated with immunotherapy. Anokion’s platform holds great potential for developing therapies for most antigen-mediated diseases in clinical applications.